Raya PM, et al. - Based on real-world evidence, researchers assessed the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) vs comparator regimens for type 2 diabetes in Spain. Clinical data were extracted from the European Xultophy Treatment Retrospective Audit study, in which patients who failed to meet glycemic goals were transferred to IDegLira. According to findings, IDegLira was found to be cost-effective in comparison with insulin regimens, with incremental cost-effectiveness ratios of EUR 3013 per quality-adjusted life-year (QALY) gained vs multiple daily insulin injections and EUR 6,890 per QALY gained vs basal insulin. Long-term projections based on real-world evidence indicated that, in this study population, IDegLira is likely to improve clinical outcomes and reduce costs or be cost-effective in vs other injectable regimens.